Scarica l'app Stockscreener
66.99
2.37%
1.55
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$65.44
Aprire:
$65.5
Volume 24 ore:
561.57K
Relative Volume:
0.24
Capitalizzazione di mercato:
$8.19B
Reddito:
$18.47M
Utile/perdita netta:
$-589.53M
Rapporto P/E:
-12.74
EPS:
-5.26
Flusso di cassa netto:
$-399.80M
1 W Prestazione:
+0.06%
1M Prestazione:
+15.84%
6M Prestazione:
+119.35%
1 anno Prestazione:
+36.44%
Intervallo 1D:
$64.80
$67.11
Intervallo di 1 settimana:
$62.86
$67.80
Portata 52W:
$29.31
$67.98
Cytokinetics Inc Stock (CYTK) Company Profile
Nome
Cytokinetics Inc
Settore
Industria
Telefono
(650) 624-3000
Indirizzo
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Confronta CYTK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
66.97 | 8.00B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.54 | 108.28B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.79 | 79.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.58 | 57.65B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
903.65 | 56.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.91 | 42.39B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Ripresa | Raymond James | Mkt Perform |
| 2025-04-24 | Iniziato | Barclays | Overweight |
| 2025-02-07 | Iniziato | Citigroup | Buy |
| 2025-01-22 | Iniziato | Stifel | Buy |
| 2024-11-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-13 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2024-01-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-07 | Iniziato | B. Riley Securities | Buy |
| 2023-08-15 | Iniziato | SVB Securities | Outperform |
| 2023-02-17 | Iniziato | BofA Securities | Neutral |
| 2022-12-23 | Reiterato | Needham | Buy |
| 2022-12-20 | Iniziato | Truist | Buy |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-01-28 | Iniziato | Goldman | Buy |
| 2021-12-22 | Iniziato | Oppenheimer | Outperform |
| 2021-12-10 | Iniziato | JP Morgan | Overweight |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2021-02-18 | Iniziato | Barclays | Overweight |
| 2021-01-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-29 | Iniziato | Goldman | Neutral |
| 2020-07-10 | Iniziato | Raymond James | Strong Buy |
| 2020-05-05 | Iniziato | Mizuho | Buy |
| 2020-04-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Ripresa | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Reiterato | Morgan Stanley | Overweight |
| 2017-11-22 | Downgrade | Needham | Strong Buy → Buy |
| 2017-11-21 | Reiterato | H.C. Wainwright | Buy |
| 2017-07-31 | Iniziato | Morgan Stanley | Overweight |
| 2017-03-08 | Iniziato | Rodman & Renshaw | Buy |
| 2017-02-06 | Aggiornamento | Needham | Buy → Strong Buy |
| 2016-12-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Reiterato | Needham | Buy |
| 2015-11-10 | Reiterato | FBR Capital | Outperform |
| 2015-11-09 | Reiterato | ROTH Capital | Buy |
| 2015-07-24 | Reiterato | MLV & Co | Buy |
| 2014-12-31 | Reiterato | ROTH Capital | Buy |
| 2014-11-04 | Aggiornamento | MLV & Co | Hold → Buy |
| 2014-04-28 | Reiterato | Needham | Buy |
Mostra tutto
Cytokinetics Inc Borsa (CYTK) Ultime notizie
Important Notice to Long-Term Shareholders of Cytokinetics, - GlobeNewswire
Cytokinetics, Incorporated $CYTK Shares Acquired by Commonwealth of Pennsylvania Public School Empls Retrmt SYS - Defense World
Cytokinetics Shares Face Critical FDA Verdict - Ad-hoc-news.de
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Ready to Jump After Recent Trade: Cytokinetics Inc (CYTK) - Setenews
Rep. Gilbert Ray Cisneros, Jr. Buys Cytokinetics, Incorporated (NASDAQ:CYTK) Stock - Defense World
How Cytokinetics Incorporated (KK3A) stock trades under stagflationWeekly Gains Report & Safe Capital Growth Trade Ideas - newser.com
What macro factors could drive Cytokinetics Incorporated (KK3A) stock higherJuly 2025 Action & Weekly Watchlist for Hot Stocks - newser.com
Insider Sell: B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Is Cytokinetics Incorporated (KK3A) stock trading at attractive multiplesJuly 2025 Trade Ideas & Safe Entry Point Alerts - newser.com
[Form 4] CYTOKINETICS INC Insider Trading Activity - Stock Titan
Cytokinetics Director Sells 5,000 Shares - TradingView
Dir Parshall Sells 5,000 ($323.7K) Of Cytokinetics Inc [CYTK] - TradingView
What market sentiment indicators show for Cytokinetics Incorporated (KK3A) stock2025 Institutional Moves & High Yield Stock Recommendations - newser.com
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea ... - Bluefield Daily Telegraph
Will Cytokinetics Incorporated (KK3A) stock draw ESG focused funds - newser.com
Cytokinetics Inc (KK3A.HM) Stock Historical Prices & Data - Yahoo! Finance Canada
Cytokinetics Inc (KK3A.HM) Latest Stock News & Headlines - Yahoo! Finance Canada
Cytokinetics Inc (KK3A.HM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Insider Sell Alert: Fady Malik Sells 2,200 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Cytokinetics Executive Sells Shares - TradingView
Cytokinetics Grants Stock Options and RSUs to New Executive and Employees as Inducements to Employment - Quiver Quantitative
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
CYTK Deadline: CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit - The Malaysian Reserve
What Does the Market Think About Cytokinetics Inc? - Benzinga
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); enCore Energy ... - Bluefield Daily Telegraph
Cytokinetics Incorporated (CYTK) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Investors in Cytokinetics, Incorporated Should Contact Levi & Korsinsky Before November 17, ... - Bluefield Daily Telegraph
Bragar Eagel & Squire, P.C. Urgently Reminds Investors of - GlobeNewswire
Total debt per share of Cytokinetics, Incorporated – DUS:KK3A - TradingView
Recover Investment Losses: Class Action Initiated Against Cytokinetics, Incorporated (CYTK) - ACCESS Newswire
Cytokinetics at Jefferies London: Aficamten’s Strategic Path Forward By Investing.com - Investing.com Canada
Cytokinetics at Jefferies London: Aficamten’s Strategic Path Forward - Investing.com India
CYTK FINAL DEADLINE: Faruqi & Faruqi, LLP Announces that Cytokinetics Investors Have Opportunity to Lead Class Action Lawsuit - Business Wire
Cytokinetics at Jefferies London: Aficamten's Strategic Path Forward - Investing.com
Cytokinetics at Jefferies London: Aficamten's Strategic Path Forward By Investing.com - Investing.com Nigeria
CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Cytokinetics, Incorporated Investors - GlobeNewswire
Securities Lawsuit Alert: Cytokinetics, Incorporated (CYTK) InvestorsContact Levi & Korsinsky Before November 17, 2025 - ACCESS Newswire
Former Exelixis GC Named Legal Chief At Cytokinetics - Law360
Cytokinetics (CYTK) Supports American Heart Association Initiati - GuruFocus
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Cytokinetics, Incorporated (CYTK) Shareholders - MarketScreener
Cytokinetics supports American Heart Association initiative to improve care for people living with hypertrophic cardiomyopathy - MarketScreener
Cytokinetics Supports American Heart Association Initiative to Enhance Care for Hypertrophic Cardiomyopathy Patients - Quiver Quantitative
Cytokinetics (Nasdaq: CYTK) backs AHA effort to expand HCM registry, reduce underdiagnosis - Stock Titan
Cytokinetics Shares Surge Amid Legal Challenges and Clinical Promise - Ad-hoc-news.de
Imbria Pharmaceuticals, Inc. announced that it has received funding from a group of investors - MarketScreener
Cytokinetics 24 Hour Deadline Alert: Former Louisiana Attorney General And Kahn Swick & Foti, LLC Remind Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Cytokinetics, IncorporatedCYTK - Louisiana First News
November 17, 2025 Deadline: Join Class Action Lawsuit Against Cytokinetics, Incorporated (CYTK)Contact Levi & Korsinsky - ACCESS Newswire
Key facts: Cytokinetics stock drops 12.98%; class action lawsuit filed - TradingView
Cytokinetics Inc Azioni (CYTK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):